Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Inc RCUS
News
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences Announces New Employment Inducement Grants
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial
Arcus Biosciences Discontinues Lung Cancer Trial With Gilead
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment — Update
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment
United States